- Home
- OKYO vs ESLA Comparison
OKYO vs ESLA Comparison
Compare OKYO & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- ESLA
- Stock Information
- Founded
- OKYO 2007
- ESLA 2021
- Country
- OKYO United Kingdom
- ESLA United States
- Employees
- OKYO N/A
- ESLA N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OKYO Health Care
- ESLA Health Care
- Exchange
- OKYO Nasdaq
- ESLA Nasdaq
- Market Cap
- OKYO 37.0M
- ESLA 35.5M
- IPO Year
- OKYO 2022
- ESLA N/A
- Fundamental
- Price
- OKYO $1.86
- ESLA $1.06
- Analyst Decision
- OKYO Strong Buy
- ESLA Strong Buy
- Analyst Count
- OKYO 1
- ESLA 1
- Target Price
- OKYO $7.00
- ESLA $16.00
- AVG Volume (30 Days)
- OKYO 163.5K
- ESLA 513.9K
- Earning Date
- OKYO 06-13-2025
- ESLA 06-17-2025
- Dividend Yield
- OKYO N/A
- ESLA N/A
- EPS Growth
- OKYO N/A
- ESLA N/A
- EPS
- OKYO N/A
- ESLA N/A
- Revenue
- OKYO N/A
- ESLA N/A
- Revenue This Year
- OKYO N/A
- ESLA $101.09
- Revenue Next Year
- OKYO N/A
- ESLA N/A
- P/E Ratio
- OKYO N/A
- ESLA N/A
- Revenue Growth
- OKYO N/A
- ESLA N/A
- 52 Week Low
- OKYO $0.81
- ESLA $0.63
- 52 Week High
- OKYO $1.98
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- OKYO 60.66
- ESLA 54.83
- Support Level
- OKYO $1.67
- ESLA $0.78
- Resistance Level
- OKYO $1.98
- ESLA $1.18
- Average True Range (ATR)
- OKYO 0.20
- ESLA 0.09
- MACD
- OKYO 0.01
- ESLA -0.00
- Stochastic Oscillator
- OKYO 80.17
- ESLA 70.00
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.